Application No. 10/750,743

Marked up version to show corrections made

Please enter the following corrections:

[0003] Atomoxetine HCl has been the subject of clinical studies for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and has received FDA approval as the prescription drug Strattera™ (Eli Lilly and Company) for the treatment of ADHD in November 2002. Atomoxetine, originally named tomoxetine, is a selective norepinephrine reuptake inhibitor. Tomoxetine was first disclosed in U.S. Pat. No. 4,314,081. Tomoxetine is also disclosed in U.S. Pat. No. 6,184,222 as a treatment for conduct disorder. The word "atomoxetine" will be used herein to refer to any acid addition salt or the free base of the molecule.

[0024] A preferred embodiment of this invention is the administration of a therapeutically effective amount of ~~Strattera™ (~~atomoxetine HCl ~~— Eli Lilly and Company)~~ to treat sexual dysfunction. Atomoxetine HCl is a selective norepinephrine reuptake inhibitor. The chemical designation is (-)-*N*-Methyl-3-phenyl-3-(*o*-tolyloxy)-propylamine hydrochloride.

[0047] A preferred embodiment of this invention is the administration of a therapeutically effective amount of atomoxetine in the hydrochloride salt form ~~Strattera™ (~~atomoxetine HCl~~)~~ to treat sexual dysfunction. The chemical designation is (-)-*N*-Methyl-3-phenyl-3-(*o*-tolyloxy)-propylamine hydrochloride. Atomoxetine HCL or other pharmaceutically acceptable salt forms are preferred embodiments of this invention.

[0052] ~~Strattera™ is formulated in capsule form. Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, or 60 mg of atomoxetine. The capsules also contain pregelatinized starch and dimethicone. The capsule shells contain gelatin, sodium lauryl sulfate, and other inactive ingredients.~~

Clean version of corrections made

[0003] Atomoxetine HCl has been the subject of clinical studies for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and has received FDA approval as the prescription drug Strattera™ (Eli Lilly and Company) for the treatment of ADHD in November 2002. Atomoxetine, originally named tomoxetine, is a selective norepinephrine reuptake inhibitor. Tomoxetine was first disclosed in U.S. Pat. No. 4,314,081. Tomoxetine is also disclosed in U.S. Pat. No. 6,184,222 as a treatment for conduct disorder. The word "atomoxetine" will be used herein to refer to any acid addition salt or the free base of the molecule.

[0024] A preferred embodiment of this invention is the administration of a therapeutically effective amount of atomoxetine HCl to treat sexual dysfunction. Atomoxetine HCl is a selective norepinephrine reuptake inhibitor. The chemical designation is (-)-*N*-Methyl-3-phenyl-3-(*o*-tolyloxy)-propylamine hydrochloride.

[0047] A preferred embodiment of this invention is the administration of a therapeutically effective amount of atomoxetine in the hydrochloride salt form atomoxetine HCl to treat sexual dysfunction. The chemical designation is (-)-*N*-Methyl-3-phenyl-3-(*o*-tolyloxy)-propylamine hydrochloride. Atomoxetine HCL or other pharmaceutically acceptable salt forms are preferred embodiments of this invention.

[0052] deleted

Conclusion

Applicant would like to thank the Examiner for his agreement to enter the corrections herein.

Application No. 10/750,743

Respectfully submitted,

Jordan A. Altabet

Address:
Jordan A. Altabet
7770 Regents Rd. #113-517
San Diego, CA 92122

Phone: 858-452-6358
Fax: 702-938-8633